Clinical trial
MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and…
NCT00284921 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00284921 |
|---|---|
| Title | MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive |
| Official title | A Twelve-month, Randomized, Multicenter, Open-label, Exploratory Study to Investigate the Clinical Outcomes of an Immunosuppressive Regimen of Basiliximab, Cyclosporine Microemulsion (CsA-ME) and Enteric-coated Mycophenolate Sodium (EC-MPS) Free of Steroids Compared With a Regimen of EC-MPS With… |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | De Novo Kidney Transplant |
| Intervention type | Drug |
| Interventions | Enteric-coated Mycophenolate sodium (EC-MPS) |
| Enrollment | 60 |
| Start date | Apr 1, 2004 |
| Primary completion | Aug 1, 2006 |
| First posted | Feb 1, 2006 |
| Last update posted | Nov 2, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: